Last reviewed · How we verify

Navoban (TROPISETRON)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 26/100

Navoban (generic name: TROPISETRON) is a tropisetron drug. It is currently FDA-approved for Chemotherapy-induced nausea and vomiting.

Navoban is a small molecule with a modality of a small molecule. It has been studied in clinical trials for conditions including analgesia, chemotherapy-induced nausea and vomiting, lung cancer, and postoperative nausea and vomiting.

At a glance

Generic nameTROPISETRON
Drug classtropisetron
Target5-hydroxytryptamine receptor 3A
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Navoban

What is Navoban?

Navoban (TROPISETRON) is a tropisetron drug, indicated for Chemotherapy-induced nausea and vomiting.

What is Navoban used for?

Navoban is indicated for Chemotherapy-induced nausea and vomiting.

What is the generic name of Navoban?

TROPISETRON is the generic (nonproprietary) name of Navoban.

What drug class is Navoban in?

Navoban belongs to the tropisetron class. See all tropisetron drugs at /class/tropisetron.

What development phase is Navoban in?

Navoban is FDA-approved (marketed).

What does Navoban target?

Navoban targets 5-hydroxytryptamine receptor 3A and is a tropisetron.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing